DUBLIN, Nov. 12, 2020 /PRNewswire/ -- Medtronic plc
(NYSE: MDT), the global leader in medical technology, today
announced the launch of InPen™ integrated with
real-time1 Guardian Connect™ CGM data. InPen is the
first and only FDA-cleared smart2 insulin pen on
the market for people on multiple daily injections (MDI). This
integrated system now provides real-time glucose readings alongside
insulin dose information giving users everything they need to
manage their diabetes in one view. Rather than switching between
apps, users have the ability to see all their information in
real-time, in one view — making it easier to make smarter dosing
decisions to manage their sugar levels.
The integration of real-time CGM data into the smart insulin pen
app is a result of the addition of Companion Medical's InPen to the
Medtronic portfolio, as of September
2020. The acquisition enables Medtronic to serve more people
— regardless of how they prefer their insulin to be delivered — and
offers a unique and expansive ecosystem of support across their
diabetes journey.
"We're strongly committed to delivering solutions that make life
easier for people living with diabetes. We're pleased to build on
the success of InPen with added real-time glucose data which
provides a complete picture for users as they look to give
themselves the right dose of insulin at the right time," said
Sean Salmon, executive vice
president and president of the Diabetes Business at Medtronic. "Our
successful integration of these devices in just two months
following the close of our Companion Medical acquisition is a
testament to the close collaboration of our employees and strong
passion to serve our customers with better solutions to manage
their diabetes."
The InPen app will continue to display information from other
currently compatible CGM systems on a three-hour delay.
About the Diabetes Business at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com),
headquartered in Dublin, Ireland,
is among the world's largest medical technology, services and
solutions companies – alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 90,000 people worldwide, serving physicians,
hospitals and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
1 Data may not appear or be delayed in certain
instances, including when there is no internet connection.
2 Smart insulin pens connect wirelessly to the
user's smartphone device and provide dosing calculations and
reminders while also integrating with advanced CG systems
Contacts:
|
|
|
|
Pamela
Reese
|
Ryan
Weispfenning
|
Public
Relations
|
Investor
Relations
|
+1-818-576-3398
|
+1-763-505-4626
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/medtronic-launches-inpen-with-real-time-guardian-connect-cgm-data--the-first-integrated-smart-insulin-pen-for-people-with-diabetes-on-mdi-301171534.html
SOURCE Medtronic plc